Scarica l'app Stockscreener
51.17
0.14%
-0.07
Dopo l'orario di chiusura:
51.17
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SUPN Giù?
Forum
Previsione
Precedente Chiudi:
$51.24
Aprire:
$51.32
Volume 24 ore:
352.74K
Relative Volume:
0.44
Capitalizzazione di mercato:
$2.93B
Reddito:
$665.13M
Utile/perdita netta:
$64.50M
Rapporto P/E:
44.72
EPS:
1.1442
Flusso di cassa netto:
$185.87M
1 W Prestazione:
+2.96%
1M Prestazione:
+8.50%
6M Prestazione:
+59.46%
1 anno Prestazione:
+34.45%
Intervallo 1D:
$50.45
$51.83
Intervallo di 1 settimana:
$47.80
$51.83
Portata 52W:
$29.16
$57.65
Supernus Pharmaceuticals Inc Stock (SUPN) Company Profile
Nome
Supernus Pharmaceuticals Inc
Settore
Telefono
301-838-2500
Indirizzo
9715 KEY WEST AVENUE, ROCKVILLE, MD
Confronta SUPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SUPN
Supernus Pharmaceuticals Inc
|
51.17 | 2.94B | 665.13M | 64.50M | 185.87M | 1.1442 |
|
ZTS
Zoetis Inc
|
126.85 | 55.38B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.37 | 50.23B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.51 | 37.17B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.83 | 21.69B | 3.08B | 1.24B | 1.07B | 25.61 |
Supernus Pharmaceuticals Inc Stock (SUPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-09 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-07-30 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2025-02-19 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-09-11 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2023-01-03 | Ripresa | Jefferies | Buy |
| 2021-12-01 | Ripresa | Jefferies | Buy |
| 2021-04-13 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-06-16 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2020-06-15 | Ripresa | Jefferies | Hold |
| 2019-11-08 | Downgrade | Berenberg | Buy → Hold |
| 2019-11-07 | Downgrade | Stifel | Buy → Hold |
| 2019-11-06 | Downgrade | Jefferies | Buy → Hold |
| 2018-11-12 | Reiterato | B. Riley FBR | Buy |
| 2018-01-18 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-28 | Reiterato | B. Riley FBR, Inc. | Buy |
| 2017-12-04 | Aggiornamento | Janney | Neutral → Buy |
| 2017-11-08 | Aggiornamento | Stifel | Hold → Buy |
| 2017-10-19 | Iniziato | FBR & Co. | Buy |
| 2017-09-19 | Downgrade | Stifel | Buy → Hold |
| 2017-07-17 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-07-14 | Iniziato | Janney | Neutral |
| 2017-06-01 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2016-07-18 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2016-07-18 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2016-02-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2015-11-05 | Reiterato | Northland Capital | Outperform |
| 2015-10-28 | Iniziato | Northland Capital | Outperform |
Mostra tutto
Supernus Pharmaceuticals Inc Borsa (SUPN) Ultime notizie
Why retail investors pile into Supernus Pharmaceuticals Inc. stockJuly 2025 Drop Watch & Technical Buy Zone Confirmation - ulpravda.ru
Will Supernus Pharmaceuticals Inc. stock deliver long term returnsEarnings Performance Report & Verified Swing Trading Watchlist - ulpravda.ru
Supernus Pharmaceuticals, Inc. (SUPN) Stock Analysis: Unlocking a 24% Potential Upside in the CNS Market - DirectorsTalk Interviews
Supernus (SUPN) Moves to Strong Buy: Rationale Behind the Upgrade - MSN
(SUPN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Supernus Pharmaceuticals Inc. (SUPN) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Supernus Pharmaceuticals Earnings Notes - Trefis
Supernus projects $600M-$630M revenue for 2025 with robust growth in core products - MSN
SUPN (Supernus Pharmaceuticals) EV-to-OCF : 37.98 (As of Dec. 25, 2025) - GuruFocus
How Supernus Pharmaceuticals Inc. (SUPN) Affects Rotational Strategy Timing - Stock Traders Daily
Supernus Pharmaceuticals Insider Sold Shares Worth $1,008,150, According to a Recent SEC Filing - marketscreener.com
Supernus Pharmaceuticals Senior VP Sells Shares - TradingView — Track All Markets
Supernus Pharmaceuticals (SUPN) Is Up 6.0% After FDA Approval Of ONAPGO Parkinson’s DrugHas The Bull Case Changed? - Sahm
Stifel Raises Price Target for Supernus Pharmaceuticals (SUPN) t - GuruFocus
Stifel raises Supernus Pharmaceuticals stock price target to $55 from $50 - Investing.com Canada
How Supernus Pharmaceuticals Inc. stock performs after earningsPortfolio Risk Report & Long Hold Capital Preservation Tips - Bölüm Sonu Canavarı
Strong Results Lifted Supernus Pharmaceuticals (SUPN) in Q3 - Finviz
Why The OLB Group, Inc. stock attracts strong analyst attention - DonanımHaber
How risky is Supernus Pharmaceuticals Inc. stock nowJuly 2025 Outlook & Fast Gaining Stock Strategy Reports - Улправда
Is Supernus Pharmaceuticals Inc. stock overvalued by current metrics2025 Market Outlook & AI Driven Price Predictions - Улправда
Has the Market Fully Recognized Supernus Pharmaceuticals’ Strong Run and Growth Prospects in 2025? - Yahoo Finance
Supernus Pharmaceuticals (SUPN): Assessing Valuation After a 33% One-Year Return and Undervalued Narrative - Yahoo Finance
SUPN to Participate in Cantor Fitzgerald Virtual Meeting - GuruFocus
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back - Yahoo Finance
Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back - The Motley Fool
Supernus Pharmaceuticals, Inc. (SUPN) Hits Fresh High: Is There Still Room to Run? - MSN
Supernus Pharmaceuticals, Inc. (SUPN) Hit a 52 Week High, Can the Run Continue? - MSN
(SUPN) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Supernus Pharmaceuticals Reports Strong Q3 2025 Growth - MSN
Supernus Pharmaceuticals Says Postpartum Depression Treatment Receives Authorization From Health Canada - marketscreener.com
Can Supernus Pharmaceuticals Inc. stock resist market sell offsRate Hike & Scalable Portfolio Growth Ideas - Newser
Supernus Pharmaceuticals, Inc.'s (NASDAQ:SUPN) Popularity With Investors Is Under Threat From Overpricing - 富途牛牛
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics ... - Enidnews.com
Supernus Pharmaceuticals to Participate in the Bank of America Securities 2025 CNS Therapeutics Virtual Conference - GlobeNewswire
Supernus Pharmaceuticals, Inc. (SUPN) Stock Forecasts - Yahoo! Finance Canada
Responsive Playbooks and the SUPN Inflection - news.stocktradersdaily.com
Supernus Pharmaceuticals Inc Stock Analysis and ForecastMerger & Acquisition Updates & Buy Sell Signal Notifications - earlytimes.in
Reversal Confirmed Inter Globe Finance Limited Stock Rallies Above MAStock Price Forecasts & High Return Capital Gain - earlytimes.in
Supernus Pharmaceuticals (SUPN) Is Down 17.4% After Raising 2025 Guidance Amid Margin and Supply Pressures – Has the Bull Case Changed? - Sahm
Is Supernus Pharmaceuticals Inc a good long term investmentChart Pattern Recognition & Small Budget Trading Portfolio - earlytimes.in
What analysts say about Supernus Pharmaceuticals Inc stockEconomic Data Impact & Outstanding Return Stocks - earlytimes.in
SUPN insider Form 4 shows 15,000-share option exercise at $12.98 - Stock Titan
Assessing Supernus Pharmaceuticals After FDA Pipeline News and 24% Jump in 2025 - Yahoo Finance
Healthcare Stocks Analysis 2025: COO & SUPN to Sell, HCA to BuyNews and Statistics - IndexBox
Assessing Supernus Pharmaceuticals (SUPN) Valuation as Shares Hold Steady Following Period of Range-Bound Trading - Sahm
Supernus Pharmaceuticals to Participate in the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Branded Pharmaceuticals Stocks Q3 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN) - Yahoo Finance
How Supernus Pharmaceuticals Inc. stock benefits from tech adoptionJuly 2025 Update & Expert Curated Trade Ideas - newser.com
Supernus (Nasdaq: SUPN) to join Piper Sandler 37th Conference fireside chat Dec. 2 - Stock Titan
Supernus to acquire depression drugmaker Sage - MSN
Supernus Pharmaceuticals Inc Azioni (SUPN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.41%
1.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):